The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly stock (NYSE: LLY) should be on your radar. Here’s why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly. Over ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

Stock splits have zero impact on a stock's underlying value. However, these splits can make shares more accessible to a greater number of retail investors as they reduce per-share ...

J. L. Bainbridge & Co. bought 61,258 shares of Eli Lilly and Company for an estimated $45.6 million in the third quarter. Post-transaction, the wealth advisory reported owning 61,782 shares of Eli ...

Eli Lilly and Company’s LLY stock has risen 18% in a month, driven mainly by a stellar third-quarter performance. Also, earlier this month, President Trump announced deals with Lilly and rival Novo ...